Ftse Mib
34.625,80
0,83%
DAX
18.772,85
0,50%
S&P 500
5.222,18
0,16%
NASDAQ
16.341,37
-0,03%
Bitcoin
60.668,05
-3,77%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ HUTCHMED China Limited (HCM) HUTCHMED China Limited (HCM) Notizie

HCM

HUTCHMED China (HCM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HCM
DataOraFonteTitoloSimboloCompagnia
08/05/202410:30GlobeNewswire Inc.HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNASDAQ:HCMHUTCHMED China Limited
26/04/202414:30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
05/04/202410:30GlobeNewswire Inc.HUTCHMED Highlights Data to be Presented at AACR Congress 2024NASDAQ:HCMHUTCHMED China Limited
02/04/202406:30GlobeNewswire Inc.HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
28/03/202401:00GlobeNewswire Inc.HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCNASDAQ:HCMHUTCHMED China Limited
22/03/202401:00GlobeNewswire Inc.HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaNASDAQ:HCMHUTCHMED China Limited
05/03/202412:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202412:40Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:HCMHUTCHMED China Limited
28/02/202412:30GlobeNewswire Inc.HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
07/02/202401:00GlobeNewswire Inc.HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionNASDAQ:HCMHUTCHMED China Limited
02/02/202409:30GlobeNewswire Inc.HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipNASDAQ:HCMHUTCHMED China Limited
01/02/202409:30GlobeNewswire Inc.HUTCHMED to Announce 2023 Final ResultsNASDAQ:HCMHUTCHMED China Limited
30/01/202405:53GlobeNewswire Inc.HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
11/01/202401:00GlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
13/12/202305:30GlobeNewswire Inc.HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsNASDAQ:HCMHUTCHMED China Limited
13/12/202301:00GlobeNewswire Inc.HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaNASDAQ:HCMHUTCHMED China Limited
01/12/202301:00GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNASDAQ:HCMHUTCHMED China Limited
10/11/202314:35GlobeNewswire Inc.Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingNASDAQ:HCMHUTCHMED China Limited
09/11/202301:11GlobeNewswire Inc.HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
01/11/202313:35GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary ReceiptsNASDAQ:HCMHUTCHMED China Limited
16/10/202310:30GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023NASDAQ:HCMHUTCHMED China Limited
29/09/202310:30GlobeNewswire Inc.HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in JapanNASDAQ:HCMHUTCHMED China Limited
12/09/202310:30GlobeNewswire Inc.HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung CancerNASDAQ:HCMHUTCHMED China Limited
12/09/202302:00GlobeNewswire Inc.HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ChinaNASDAQ:HCMHUTCHMED China Limited
29/08/202302:00GlobeNewswire Inc.HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric CancerNASDAQ:HCMHUTCHMED China Limited
21/08/202302:00GlobeNewswire Inc.HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in ChinaNASDAQ:HCMHUTCHMED China Limited
31/07/202313:41GlobeNewswire Inc.HUTCHMED Reports 2023 Interim Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
20/07/202302:00GlobeNewswire Inc.HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration StudyNASDAQ:HCMHUTCHMED China Limited
13/07/202310:30GlobeNewswire Inc.HUTCHMED Announces Changes to Board of Directors and Technical Committee NASDAQ:HCMHUTCHMED China Limited
10/07/202302:00GlobeNewswire Inc.HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in ChinaNASDAQ:HCMHUTCHMED China Limited
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HCM

La tua Cronologia

COIN
MOCOKRW
Moss Coin
NYSE
BG
Bunge Global
TSXV
RGG
React Gaming
GATE
GSEETH
GSENetwork
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network